R Sindhu Priya, R Swathi, S Tamil Selvi, D Anitha, M Kavitha, R Hemavathi, C Keerthika
{"title":"评估四棱松对绝经后骨质疏松妇女的疗效的研究。","authors":"R Sindhu Priya, R Swathi, S Tamil Selvi, D Anitha, M Kavitha, R Hemavathi, C Keerthika","doi":"10.4103/jpbs.jpbs_574_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Osteopenia refers to bone density that is not only normal but also not as low as that noted in osteoporosis. Osteopenia leads to osteoporosis and increases the risk of fractures. Current research is focused on agents that will prevent or slow the progression of bone loss.</p><p><strong>The objectives of the study: </strong>To assess the pretest and posttest levels of osteopenia among postmenopausal women, and to assess the effectiveness of Cissus quadrangularis (CQ) on postmenopausal women with osteopenia.</p><p><strong>Methodology: </strong>A true experimental study design using targeted sampling techniques was used to conduct 60 patients with osteopenia. The data were collected with the help of structured questionnaires. Confidentiality was maintained throughout the process. The data collected were analyzed using descriptive and inference statistics.</p><p><strong>Result: </strong>A total of 60 participants completed this study. The percent BMD changes in the CQ-treated groups did not differ at any site after 24 weeks compared to the placebo. Reduced bone remodeling activity was detected in both CQ-treated groups. These results correlated with the within-group comparison, which showed a continuously significant increase in both BTMs in the placebo group.</p><p><strong>Conclusion: </strong>This is the first clinical report that showed a promising effect on delaying bone loss of oral administration of CQ for 24 weeks, as indicated by a slower bone remodeling process via a reduction in BTMs. However, no change in BMD was observed.</p>","PeriodicalId":94339,"journal":{"name":"Journal of pharmacy & bioallied sciences","volume":"16 Suppl 3","pages":"S2889-S2891"},"PeriodicalIF":0.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11426915/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Study to Assess the Effectiveness of Cissus Quadrangularis among Postmenopausal Women with Osteopenia.\",\"authors\":\"R Sindhu Priya, R Swathi, S Tamil Selvi, D Anitha, M Kavitha, R Hemavathi, C Keerthika\",\"doi\":\"10.4103/jpbs.jpbs_574_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Osteopenia refers to bone density that is not only normal but also not as low as that noted in osteoporosis. Osteopenia leads to osteoporosis and increases the risk of fractures. Current research is focused on agents that will prevent or slow the progression of bone loss.</p><p><strong>The objectives of the study: </strong>To assess the pretest and posttest levels of osteopenia among postmenopausal women, and to assess the effectiveness of Cissus quadrangularis (CQ) on postmenopausal women with osteopenia.</p><p><strong>Methodology: </strong>A true experimental study design using targeted sampling techniques was used to conduct 60 patients with osteopenia. The data were collected with the help of structured questionnaires. Confidentiality was maintained throughout the process. The data collected were analyzed using descriptive and inference statistics.</p><p><strong>Result: </strong>A total of 60 participants completed this study. The percent BMD changes in the CQ-treated groups did not differ at any site after 24 weeks compared to the placebo. Reduced bone remodeling activity was detected in both CQ-treated groups. These results correlated with the within-group comparison, which showed a continuously significant increase in both BTMs in the placebo group.</p><p><strong>Conclusion: </strong>This is the first clinical report that showed a promising effect on delaying bone loss of oral administration of CQ for 24 weeks, as indicated by a slower bone remodeling process via a reduction in BTMs. However, no change in BMD was observed.</p>\",\"PeriodicalId\":94339,\"journal\":{\"name\":\"Journal of pharmacy & bioallied sciences\",\"volume\":\"16 Suppl 3\",\"pages\":\"S2889-S2891\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11426915/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmacy & bioallied sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jpbs.jpbs_574_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacy & bioallied sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jpbs.jpbs_574_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
The Study to Assess the Effectiveness of Cissus Quadrangularis among Postmenopausal Women with Osteopenia.
Background: Osteopenia refers to bone density that is not only normal but also not as low as that noted in osteoporosis. Osteopenia leads to osteoporosis and increases the risk of fractures. Current research is focused on agents that will prevent or slow the progression of bone loss.
The objectives of the study: To assess the pretest and posttest levels of osteopenia among postmenopausal women, and to assess the effectiveness of Cissus quadrangularis (CQ) on postmenopausal women with osteopenia.
Methodology: A true experimental study design using targeted sampling techniques was used to conduct 60 patients with osteopenia. The data were collected with the help of structured questionnaires. Confidentiality was maintained throughout the process. The data collected were analyzed using descriptive and inference statistics.
Result: A total of 60 participants completed this study. The percent BMD changes in the CQ-treated groups did not differ at any site after 24 weeks compared to the placebo. Reduced bone remodeling activity was detected in both CQ-treated groups. These results correlated with the within-group comparison, which showed a continuously significant increase in both BTMs in the placebo group.
Conclusion: This is the first clinical report that showed a promising effect on delaying bone loss of oral administration of CQ for 24 weeks, as indicated by a slower bone remodeling process via a reduction in BTMs. However, no change in BMD was observed.